Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Zenas BioPharma, Inc. Common Stock (ZBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ZBIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -40.73% | Avg. Invested days 14 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 171017 | Beta - | 52 Weeks Range 5.83 - 26.25 | Updated Date 03/25/2025 |
52 Weeks Range 5.83 - 26.25 | Updated Date 03/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -95131473 | Price to Sales(TTM) - |
Enterprise Value -95131473 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 10.43 | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating 4.6 | Target Price - | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Zenas BioPharma, Inc. Common Stock
Company Overview
History and Background
Zenas BioPharma, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases. Founded in 2021, it is a relatively new company aiming to address significant unmet needs in immunology.
Core Business Areas
- Immunology: Zenas BioPharma focuses on developing therapies for autoimmune diseases, including those with high unmet needs. They are developing novel treatments.
Leadership and Structure
The leadership team consists of experienced executives in the biopharmaceutical industry. The organizational structure is typical of a biotech company, with research, development, and commercial functions.
Top Products and Market Share
Key Offerings
- Obexelimab: Obexelimab is a novel, fully human, Fc-engineered monoclonal antibody designed to target CD19-expressing B cells. It's in development for the treatment of autoimmune diseases. There is no current market share yet, but the competitive landscape includes companies like Roche (RHHBY), Bristol Myers Squibb (BMY) and Johnson and Johnson (JNJ).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investment in research and development. The autoimmune disease segment is growing due to an increasing prevalence of these conditions and advances in treatment options.
Positioning
Zenas BioPharma aims to differentiate itself by focusing on novel mechanisms of action and targeting specific patient populations within the autoimmune space.
Total Addressable Market (TAM)
The total addressable market for autoimmune disease therapies is estimated to be in the billions of dollars annually. Zenas BioPharma is positioning itself to capture a share of this market with its pipeline of innovative therapies.
Upturn SWOT Analysis
Strengths
- Novel technology platform
- Experienced management team
- Focus on high-unmet-need areas
Weaknesses
- Limited product portfolio
- Reliance on clinical trial success
- Dependence on funding
Opportunities
- Partnerships and collaborations
- Expansion into new therapeutic areas
- Positive clinical trial results
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- RHHBY
- BMY
- JNJ
Competitive Landscape
Zenas BioPharma faces competition from established pharmaceutical companies with larger resources and broader product portfolios. Its advantage lies in its novel technology and focus on specific autoimmune diseases.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancement of its product pipeline through preclinical and clinical stages.
Future Projections: Future growth is contingent on successful clinical trial outcomes and regulatory approvals. Analyst estimates are based on the potential market opportunity for its lead drug candidate, obexelimab, and other pipeline assets.
Recent Initiatives: Recent initiatives include advancing obexelimab in clinical trials, expanding its pipeline through internal development and potential acquisitions or licensing.
Summary
Zenas BioPharma is a clinical-stage biopharmaceutical company with a focus on autoimmune diseases. Its success hinges on positive clinical trial results for its lead drug candidate, obexelimab, and other pipeline assets. The company faces competition from larger, established pharmaceutical companies, but its novel technology and focus on unmet needs provide potential for growth. Zenas BioPharma needs to secure adequate funding to support its clinical development programs and navigate the regulatory landscape effectively. The company will be monitoring competitors in the space and the latest developments in autoimmune therapies.
Similar Companies
- RHHBY
- BMY
- JNJ
- ABBV
- AMGN
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zenas BioPharma, Inc. Common Stock
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2024-09-13 | CEO & Chairman of the Board Mr. Leon Oliver Moulder Jr., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 130 | Website https://zenasbio.com |
Full time employees 130 | Website https://zenasbio.com | ||
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind both CD19 and Fc"RIIb for the treatment of several I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.